Skip to content

Author

Jaroslav Zak

We have 2 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

23 PRISM: Phase 1b of Retifanlimab and Ruxolitinib in Solid Malignancies Progressing on Prior Checkpoint Inhibition (NCT07219576)

The vision is to establish JAK inhibition as a tractable strategy for restoring checkpoint sensitivity across solid tumors, providing the foundation for a biomarker-driven randomized phase 2 trial in checkpoint-refractory disease.

Rana Mckay, L.-J. Wei, Yu-Wei Chen et al. · 0 citations
Open access Jul 2026

An IL-34–IGF-1 inflammatory axis fuels KRAS-mutant lung cancer progression

It is shown that KRASG12D mutations in lung epithelium drive proliferation of resident, embryonically-derived alveolar macrophages, which then promote tumor cell proliferation and protection from ferroptosis, leading to tumor progression.

Jaroslav Zak, Hui Chen, Erpei Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.